NZ626242A - Anti-asic1 antibodies and uses thereof - Google Patents

Anti-asic1 antibodies and uses thereof

Info

Publication number
NZ626242A
NZ626242A NZ626242A NZ62624213A NZ626242A NZ 626242 A NZ626242 A NZ 626242A NZ 626242 A NZ626242 A NZ 626242A NZ 62624213 A NZ62624213 A NZ 62624213A NZ 626242 A NZ626242 A NZ 626242A
Authority
NZ
New Zealand
Prior art keywords
asic1
antibodies
asic1 antibodies
antigen
disorders
Prior art date
Application number
NZ626242A
Other languages
English (en)
Inventor
Lynn Macdonald
Min Gao
Marc R Morra
Nicole M Alessandri-Haber
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ626242(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ626242A publication Critical patent/NZ626242A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ626242A 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof NZ626242A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24
PCT/US2013/023784 WO2013116296A1 (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
NZ626242A true NZ626242A (en) 2017-02-24

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ626242A NZ626242A (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Country Status (33)

Country Link
US (3) US9150648B2 (https=)
EP (2) EP3453723B1 (https=)
JP (1) JP6302844B2 (https=)
KR (1) KR102111941B1 (https=)
CN (1) CN104093738B (https=)
AR (1) AR089852A1 (https=)
AU (1) AU2013215254B2 (https=)
CA (1) CA2862332C (https=)
CL (1) CL2014002019A1 (https=)
CO (1) CO7020877A2 (https=)
CY (2) CY1121368T1 (https=)
DK (2) DK3453723T3 (https=)
EA (1) EA028647B1 (https=)
ES (2) ES2886123T3 (https=)
HR (2) HRP20211541T1 (https=)
HU (2) HUE056335T2 (https=)
IL (2) IL233410A0 (https=)
IN (1) IN2014CN04645A (https=)
JO (1) JO3547B1 (https=)
LT (2) LT2809681T (https=)
MX (1) MX358518B (https=)
MY (1) MY168748A (https=)
NZ (1) NZ626242A (https=)
PH (1) PH12014501613B1 (https=)
PL (2) PL3453723T3 (https=)
PT (2) PT3453723T (https=)
RS (2) RS62454B1 (https=)
SG (1) SG11201403222UA (https=)
SI (2) SI3453723T1 (https=)
SM (1) SMT202100628T1 (https=)
TW (1) TWI591073B (https=)
UY (1) UY34603A (https=)
WO (1) WO2013116296A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3453723B1 (en) 2012-01-31 2021-08-11 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
KR20160138580A (ko) 2014-04-15 2016-12-05 소렌토 쎄라퓨틱스, 인코포레이티드 Wisp1에 결합하는 항원 결합 단백질
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
PL3248986T3 (pl) 2014-05-16 2022-05-16 Ablynx Nv Domeny zmienne immunoglobuliny
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
LT3638698T (lt) * 2018-01-26 2021-04-12 Regeneron Pharmaceuticals, Inc. Antikūnai prieš tmprss2 ir antigeną surišantys fragmentai
AU2019449475A1 (en) * 2019-06-04 2022-01-06 Shanghaitech University Affinity-maturated anti-ASIC1a antibodies
CN118955717A (zh) * 2019-07-11 2024-11-15 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
AU2019457621A1 (en) * 2019-07-23 2022-02-17 Shanghaitech University ASIC1 channel antagonist antibody
JP7796008B2 (ja) * 2019-09-13 2026-01-08 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３７１抗体およびその使用
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
WO2023034566A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-dll3 antibodies and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ATE347596T1 (de) 1997-10-29 2006-12-15 Univ Mcgill Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
CA2538754A1 (en) * 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
EP1734962A4 (en) 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
BRPI0519596B1 (pt) * 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
CA2763671A1 (en) * 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
US8618113B2 (en) 2006-07-14 2013-12-31 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
EP2137539B1 (en) 2007-04-03 2010-10-06 ILEGUSAVNID, Genetics Resource Centre Minestry of Social Affairs and Health Amiloride sensitive sodium channels associated with panic disorders
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
EP3453723B1 (en) 2012-01-31 2021-08-11 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Also Published As

Publication number Publication date
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
DK2809681T3 (en) 2019-03-11
EP2809681A1 (en) 2014-12-10
ES2886123T3 (es) 2021-12-16
IN2014CN04645A (https=) 2015-09-18
SI2809681T1 (sl) 2019-04-30
AU2013215254B2 (en) 2017-08-31
MX2014008541A (es) 2014-10-24
KR20140125363A (ko) 2014-10-28
LT2809681T (lt) 2019-02-11
US9150648B2 (en) 2015-10-06
ES2707599T3 (es) 2019-04-04
EP3453723B1 (en) 2021-08-11
CN104093738B (zh) 2018-05-18
HRP20190358T1 (hr) 2019-04-05
SMT202100628T1 (it) 2022-01-10
PH12014501613A1 (en) 2014-10-13
PH12014501613B1 (en) 2014-10-13
JP6302844B2 (ja) 2018-03-28
DK3453723T3 (da) 2021-09-13
SG11201403222UA (en) 2014-07-30
US10513557B2 (en) 2019-12-24
BR112014018651A2 (pt) 2017-07-04
MY168748A (en) 2018-11-30
EP3453723A3 (en) 2019-04-10
US20180222976A1 (en) 2018-08-09
PL3453723T3 (pl) 2022-01-03
AU2013215254A1 (en) 2014-07-03
RS58439B1 (sr) 2019-04-30
HRP20211541T1 (hr) 2021-12-24
TWI591073B (zh) 2017-07-11
PT2809681T (pt) 2019-02-18
JP2015508063A (ja) 2015-03-16
HUE042531T2 (hu) 2019-07-29
EA201491452A1 (ru) 2014-11-28
CA2862332A1 (en) 2013-08-08
EP3453723A2 (en) 2019-03-13
IL233410A0 (en) 2014-08-31
SI3453723T1 (sl) 2021-11-30
PL2809681T3 (pl) 2019-05-31
HUE056335T2 (hu) 2022-02-28
IL254416A0 (en) 2017-11-30
AR089852A1 (es) 2014-09-24
US20130195878A1 (en) 2013-08-01
MX358518B (es) 2018-08-24
CA2862332C (en) 2021-05-18
EP2809681B1 (en) 2018-12-05
WO2013116296A1 (en) 2013-08-08
RS62454B1 (sr) 2021-11-30
CY1124778T1 (el) 2022-11-25
CY1121368T1 (el) 2020-05-29
CL2014002019A1 (es) 2015-01-16
KR102111941B1 (ko) 2020-05-18
PT3453723T (pt) 2021-09-07
IL254416B (en) 2018-03-29
UY34603A (es) 2013-07-31
LT3453723T (lt) 2021-09-10
TW201335182A (zh) 2013-09-01
CN104093738A (zh) 2014-10-08
US20160002332A1 (en) 2016-01-07
JO3547B1 (ar) 2020-07-05
HK1199269A1 (en) 2015-06-26

Similar Documents

Publication Publication Date Title
NZ626242A (en) Anti-asic1 antibodies and uses thereof
NZ707086A (en) Anti-cd40 antibodies and methods of use
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
SG194701A1 (en) Anti-cd40 antibodies and methods of use
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
MY185813A (en) Factor xi antibodies and methods of use
MX2015000863A (es) Anticuerpos anti-siglec-15.
PH12016500425A1 (en) Il-18 binding protein (il-18bp) in inflammatory diseases
EP2582722A4 (en) ANTIBODIES AGAINST GD2
BR112018068678A2 (pt) anticorpos anti-mica
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2015017853A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
PH12015502829A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
MX360163B (es) Moleculas de union il-6.
PH12014502582B1 (en) Anti-TG2 Antibodies and Methods for Using the Same
MX2014012843A (es) Anticuerpos anti-pdgf-c.
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
TN2013000045A1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
WO2014172653A3 (en) Anti-notch1 antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JAN 2020 BY WATERMARK INTELLECTUAL PROPERTY PTY LTD.

Effective date: 20170525

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2021 BY ANAQUA SERVICES

Effective date: 20191218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2022 BY ANAQUA SERVICES

Effective date: 20201217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2023 BY ANAQUA SERVICES

Effective date: 20211215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2024 BY ANAQUA SERVICES

Effective date: 20221221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2025 BY ANAQUA SERVICES

Effective date: 20231220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2026 BY ANAQUA SERVICES

Effective date: 20241218